The Cooper Companies, Inc. (NASDAQ:COO) Given Average Recommendation of “Moderate Buy” by Brokerages

The Cooper Companies, Inc. (NASDAQ:COO) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $117.00.

A number of brokerages recently weighed in on COO. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Wells Fargo & Company boosted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Morgan Stanley lowered their price target on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Finally, Citigroup reduced their price objective on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a report on Friday, December 6th.

Cooper Companies Trading Down 1.8 %

Shares of COO stock opened at $93.57 on Monday. Cooper Companies has a 52-week low of $84.76 and a 52-week high of $112.38. The company has a 50-day simple moving average of $94.99 and a two-hundred day simple moving average of $99.85. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The company has a market capitalization of $18.67 billion, a price-to-earnings ratio of 47.98, a PEG ratio of 2.41 and a beta of 1.00.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Cooper Companies’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period last year, the company posted $0.87 earnings per share. Research analysts anticipate that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Trading of Cooper Companies

A number of institutional investors have recently added to or reduced their stakes in COO. Victory Capital Management Inc. increased its position in shares of Cooper Companies by 23.0% during the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after buying an additional 737,726 shares during the period. Highland Capital Management LLC bought a new stake in Cooper Companies during the 4th quarter worth approximately $4,004,000. Franklin Resources Inc. increased its holdings in Cooper Companies by 194.0% during the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock worth $5,265,000 after acquiring an additional 32,260 shares during the period. Principal Financial Group Inc. boosted its holdings in Cooper Companies by 6.6% in the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after purchasing an additional 14,687 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after purchasing an additional 573,908 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.